481 related articles for article (PubMed ID: 33755863)
21. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).
Zhu XD; Huang MZ; Wang YS; Feng WJ; Chen ZY; He YF; Zhang XW; Liu X; Wang CC; Zhang W; Ying JE; Wu J; Yang L; Qin YR; Luo JF; Zhao XY; Li WH; Zhang Z; Qiu LX; Geng QR; Zou JL; Zhang JY; Zheng H; Song XF; Wu SS; Zhang CY; Gong Z; Liu QQ; Wang XF; Xu Q; Wang Q; Ji JM; Zhao J; Guo WJ
Cancer Commun (Lond); 2022 Apr; 42(4):314-326. PubMed ID: 35212487
[TBL] [Abstract][Full Text] [Related]
22. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
[TBL] [Abstract][Full Text] [Related]
23. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
[TBL] [Abstract][Full Text] [Related]
24. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
[TBL] [Abstract][Full Text] [Related]
25. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Hall PS; Lord SR; Collinson M; Marshall H; Jones M; Lowe C; Howard H; Swinson D; Velikova G; Anthoney A; Roy R; Dent J; Cheeseman S; Last K; Seymour MT
Br J Cancer; 2017 Feb; 116(4):472-478. PubMed ID: 28095397
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
27. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Raimondi A; Di Maio M; Morano F; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Sartore-Bianchi A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Adamo V; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Bergamo F; Niger M; Antista M; Peverelli G; de Braud F; Di Bartolomeo M; Pietrantonio F
Eur J Cancer; 2020 Aug; 135():230-239. PubMed ID: 32623288
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Efficacy of Aspirin Plus EOX vs. EOX Alone in Patients with Locally Advanced and Metastatic Gastric Cancer: a Randomized Clinical Trial.
Jafa E; L C; Nisha Y; Kate V; Kayal S; Ganesh RN; V C S; Ganesan P; Penumadu P; Dubashi B
J Gastrointest Cancer; 2023 Jun; 54(2):642-650. PubMed ID: 35842566
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract][Full Text] [Related]
34. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Pluschnig U; Schoppmann SF; Preusser M; Datler P; Asari R; Ba-Ssalamah A; Schwameis K; Birner P; Zacherl J; Hejna M
Anticancer Res; 2013 Mar; 33(3):1035-9. PubMed ID: 23482778
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
36. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
[TBL] [Abstract][Full Text] [Related]
37. Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.
Brehler AC; Hartmann W; Wiebe S; Kerkhoff A; Schliemann C; Palmes D; Senninger N; Lenze F; Ullerich H; Berdel WE; Kessler T
PLoS One; 2015; 10(4):e0122974. PubMed ID: 25855972
[TBL] [Abstract][Full Text] [Related]
38. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Mongan AM; Kalachand R; King S; O'Farrell NJ; Power D; Ravi N; Muldoon C; O'Byrne K; Reynolds JV
Ir J Med Sci; 2015 Jun; 184(2):417-23. PubMed ID: 24879337
[TBL] [Abstract][Full Text] [Related]
40. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
